顺-1,3-环己烷二甲酸 | 2305-31-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 顺-1,3-环己烷二甲酸
• 中文别名: 顺式-1,3-环己烷二甲酸；顺-1,3-环己烷二羧酸
• 英文名称: cis-cyclohexane-1,3-dicarboxylic acid
• 英文别名: meso-cis-1,3-cyclohexanedicarboxylic acid；cis-e,e-1,3-cyclohexanedicarboxylic acid；cis-1,3-cyclohexane dicarboxylic acid；cis-1,3-cyclohexanedicarboxylic acid；cis-1,3-cyclohexanedicarboxylicacid；cis-1,3-cyclohexanedicarbonsaeure；(1S,3R)-cyclohexane-1,3-dicarboxylic acid
• CAS: 2305-31-9
• 化学式: C₈H₁₂O₄
• mdl: MFCD01311240
• 分子量: 172.181
• InChiKey: XBZSBBLNHFMTEB-OLQVQODUSA-N

物化性质

• 熔点：
  165 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2917209090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥

SDS

---

Section I.Chemical Product and Company Identification
Chemical Name cis-1,3-Cyclohexanedicarboxylic Acid
Portland OR
Synonym 1,3-Cyclohexanedicarboxylic acid,
(1R,3S)-rel- (CA INDEX NAME)
C8H12O4
Chemical Formula
CAS Number 2305-31-9

---

Section II. Composition and Information on Ingredients
Chemical Name CAS Number Percent (%) TLV/PEL Toxicology Data
cis-1,3-Cyclohexanedicarboxylic Acid 2305-31-9 Min. 98.0 Not available. Not available.
(GC,T)

---

Section III. Hazards Identification
Acute Health Effects No specific information is available in our data base regarding the toxic effects of this material for humans. However,
exposure to any chemical should be kept to a minimum. Skin and eye contact may result in irritation. May be harmful if
inhaled or ingested. Always follow safe industrial hygiene practices and wear proper protective equipment when handling
this compound.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
CARCINOGENIC EFFECTS : Not available.
Chronic Health Effects
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.

---

Section IV. First Aid Measures
Eye Contact Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Get medical attention.
Skin Contact In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash clothing
before reuse. Thoroughly clean shoes before reuse. Get medical attention.
Inhalation If the victim is not breathing, perform mouth-to-mouth resuscitation. Loosen tight clothing such as a collar, tie, belt or
waistband. If breathing is difficult, oxygen can be administered. Seek medical attention if respiration problems do not
improve.
Ingestion INDUCE VOMITING by sticking finger in throat. Lower the head so that the vomit will not reenter the mouth and throat.
Loosen tight clothing such as a collar, tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that the
toxic material was ingested; the absence of such signs, however, is not conclusive.

---

Section V. Fire and Explosion Data
Auto-Ignition Not available.
Flammability May be combustible at high temperature.
Flash Points Flammable Limits Not available.
Not available.
Combustion Products These products are toxic carbon oxides (CO, CO 2).
Fire Hazards
Not available.
Risks of explosion of the product in presence of mechanical impact: Not available.
Explosion Hazards
Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting Media
SMALL FIRE: Use DRY chemical powder.
and Instructions LARGE FIRE: Use water spray, fog or foam. DO NOT use water jet.
Consult with local fire authorities before attempting large scale fire-fighting operations.
Continued on Next Page
cis-1,3-Cyclohexanedicarboxylic Acid

---

Section VI. Accidental Release Measures
Spill Cleanup Use a shovel to put the material into a convenient waste disposal container. Finish cleaning the spill by rinsing any
Instructions contaminated surfaces with copious amounts of water. Consult federal, state, and/or local authorities for assistance on
disposal.

---

Section VII. Handling and Storage
Handling and Storage Keep away from heat. Mechanical exhaust required. When not in use, tightly seal the container and store in a dry, cool
place. Avoid excessive heat and light. Do not breathe dust.
Information
Always store away from incompatible compounds such as oxidizing agents.

---

Section VIII. Exposure Controls/Personal Protection
Engineering Controls Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal Protection Splash goggles. Lab coat. Dust respirator. Boots. Gloves. Suggested protective clothing might not be sufficient; consult
a specialist BEFORE handling this product. Be sure to use a MSHA/NIOSH approved respirator or equivalent.
Exposure Limits Not available.

---

Section IX. Physical and Chemical Properties
Solid. Solubility
Physical state @ 20°C Not available.
Not available.
Specific Gravity
Molecular Weight 172.18 Partition Coefficient Not available.
Boiling Point
Not available. Vapor Pressure Not applicable.
Melting Point 165°C (329°F) Vapor Density Not available.
Refractive Index Not available. Volatility Not available.
Critical Temperature Not available. Odor Not available.
Viscosity Not available. Taste Not available.

---

Section X. Stability and Reactivity Data
Stability

---

This material is stable if stored under proper conditions. (See Section VII for instructions)
Conditions of Instability Avoid excessive heat and light.
Incompatibilities
Reactive with oxidizing agents.

---

Section XI. Toxicological Information
RTECS Number Not available.
Eye Contact. Ingestion. Inhalation.
Routes of Exposure
Toxicity Data Not available.
Chronic Toxic Effects CARCINOGENIC EFFECTS : Not available.
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.
Acute Toxic Effects No specific information is available in our data base regarding the toxic effects of this material for humans. However,
exposure to any chemical should be kept to a minimum. Skin and eye contact may result in irritation. May be harmful if
inhaled or ingested. Always follow safe industrial hygiene practices and wear proper protective equipment when handling
this compound.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
Continued on Next Page
cis-1,3-Cyclohexanedicarboxylic Acid

---

Section XII. Ecological Information
Ecotoxicity Not available.
Environmental Fate Not available.

---

Section XIII. Disposal Considerations
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material with a
Waste Disposal
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system. Observe all
federal, state and local regulations when disposing of the substance.

---

Section XIV. Transport Information
DOT Classification Not a DOT controlled material (United States).
PIN Number Not applicable.
Proper Shipping Name
Not applicable.
Packing Group (PG) Not applicable.
DOT Pictograms

---

Section XV. Other Regulatory Information and Pictograms
TSCA Chemical Inventory This product is NOT on the EPA Toxic Substances Control Act (TSCA) inventory. The following notices are required by 40
CFR 720.36 (C) for those products not on the inventory list:
(EPA)
(i) These products are supplied solely for use in research and development by or under the supervision of a technically
qualified individual as defined in 40 CFR 720.0 et sec.
(ii) The health risks of these products have not been fully determined. Any information that is or becomes available will be
supplied on an MSDS sheet.
WHMIS Classification Not controlled under WHMIS (Canada).
(Canada)
EINECS Number (EEC) Not available.
EEC Risk Statements Not available.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  顺-1,3-环己烷二甲酸 在 四丙基溴化铵 、 溴 、 magnesium sulfate 、 mercury(II) oxide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 1,3-环己二烯
  参考文献：
  名称：

  Hoffmann, Joachim; Voss, Juergen, Chemische Berichte, 1992, vol. 125, # 6, p. 1415 - 1420

  摘要：

  DOI：
• 作为产物：
  描述：

  cis-dimethyl cyclohex-4-ene-1,3-dicarboxylate 生成 顺-1,3-环己烷二甲酸
  参考文献：
  名称：

  Palladium(II)-catalyzed carboxylation reactions of olefins: scope and utility

  摘要：

  DOI：

  10.1021/jo01334a006
• 作为试剂：
  描述：

  己酰氯 在 三氯化铝 、 顺-1,3-环己烷二甲酸 作用下， 以 硝基甲烷 为溶剂， 反应 3.0h， 以26.9%的产率得到7-butyl-tridecane-6,8-dione
  参考文献：
  名称：

  Matoba, Katsuhide; Tachi, Masashi; Itooka, Toshiyuki, Chemical and pharmaceutical bulletin, 1986, vol. 34, # 5, p. 2007 - 2012

  摘要：

  DOI：

文献信息

• Inhibitors of protein kinases
  申请人：Zeitlmann Lutz

  公开号：US20110224225A1

  公开（公告）日：2011-09-15

  Compounds of general Formula (I): wherein R 1 , R 2 , R 3 , R a , A, B and x are as defined herein are inhibitors of protein kinases in particular members of the cyclin-dependent kinase family and/or the glycogen synthase kinase 3 family and are useful in preventing and/or treating any type of pain, inflammatory disorders, cancer, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases, metabolic disorders, renal diseases, neurologic and neuropsychiatric diseases and neurodegenerative diseases.

  通用式(I)的化合物： 其中R1、R2、R3、Ra、A、B和x的定义如本文所述，是特定于细胞周期蛋白激酶家族和/或糖原合成酶激酶3家族的抑制剂，并且在预防和/或治疗任何类型的疼痛、炎症性疾病、癌症、免疫性疾病、增殖性疾病、传染病、心血管疾病、代谢性疾病、肾脏疾病、神经和神经精神疾病以及神经退行性疾病方面具有用处。
• [EN] BIPOLAR TETRAETHER LIPIDS<br/>[FR] LIPIDES BIPOLAIRES DE TYPE TÉTRAÉTHER
  申请人：UNIV CALIFORNIA

  公开号：WO2017040702A1

  公开（公告）日：2017-03-09

  Disclosed herein, inter alia, are compounds, compositions, and liposomes and methods of thereof.

  披露的内容包括但不限于化合物、组合物、脂质体及其方法。
• Imidazole Derivative
  申请人：Machinaga Nobuo

  公开号：US20120316170A1

  公开（公告）日：2012-12-13

  To provide a novel compound or an isotope thereof or a pharmaceutically acceptable salt thereof having S1P lyase inhibitory capacity and inducing the decrease in number of lymphocytes, and a pharmaceutical composition containing these as active ingredients. A compound represented by the general formula (I): or the general formula (II): or an isotope thereof or a pharmaceutically acceptable salt thereof.

  提供具有S1P裂解酶抑制能力并诱导淋巴细胞数量减少的新型化合物或其同位素或其药用可接受盐，以及含有这些化合物作为活性成分的药物组合物。由一般式(I)表示的化合物： 或一般式(II)： 或其同位素或其药用可接受盐。
• Efficient and Practical Arene Hydrogenation by Heterogeneous Catalysts under Mild Conditions
  作者：Tomohiro Maegawa、Akira Akashi、Kiichiro Yaguchi、Yohei Iwasaki、Masahiro Shigetsura、Yasunari Monguchi、Hironao Sajiki

  DOI：10.1002/chem.200900361

  日期：2009.7.13

  An efficient and practical arene hydrogenation procedure based on the use of heterogeneous platinum group catalysts has been developed. Rh/C is the most effective catalyst for the hydrogenation of the aromatic ring, which can be conducted in iPrOH under neutral conditions and at ordinary to medium H2 pressures (<10 atm). A variety of arenes such as alkylbenzenes, benzoic acids, pyridines, furans, are

  已经开发了基于使用异质铂族催化剂的有效和实用的芳烃加氢方法。Rh / C是最有效的芳环加氢催化剂，可以在中性条件下，在常压至中等H 2压力（<10 atm）下在i PrOH中进行。将各种芳烃（如烷基苯，苯甲酸，吡啶，呋喃）以良好或极好的收率氢化成相应的环己基和杂环化合物。Ru / C的使用比Rh / C便宜，它为氢化包括苯酚在内的芳烃提供了一种有效而实用的方法。在简单过滤后，两种催化剂都可以重复使用数次，而催化活性没有任何重大损失。
• Bifunctional cytotoxic agents
  申请人：Pfizer Inc.

  公开号：US10086085B2

  公开（公告）日：2018-10-02

  Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.

  细胞毒性二聚体，包括基于CBI和/或基于CPI的亚单位，抗体药物偶联物包括这样的二聚体，以及使用同一方法治疗癌症和其他疾病。

表征谱图